Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...
H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CYTK stock, giving a Buy rating on January 14.Invest with ...
Cytokinetics, Incorporated has announced the enrollment opening for AMBER-HFpEF, a Phase 2 randomized, placebo-controlled clinical trial evaluating the safety and tolerability of CK-586 in ...
Zacks.com on MSN4d
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure StudyCytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.
“In addition, we are advancing our later-stage development programs for omecamtiv mecarbil and CK-586 in adjacent specialty cardiology indications with intention to further augment our pipeline ...
"In addition, we are advancing our later-stage development programs for omecamtiv mecarbil and CK-586 in adjacent specialty cardiology indications with intention to further augment our pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback